Entering text into the input field will update the search result below

BridgeBio Pharma Stock Forecast: A Long-Term Buy Or Sell

May 03, 2021 11:20 AM ETBridgeBio Pharma, Inc. (BBIO)XBI4 Comments


  • 2021 is set to be a pivotal year for BridgeBio Pharma with several catalysts across a growing pipeline of candidate genetic medicines.
  • The company's unique R&D strategy based on partnerships with academic institutions supports the ability to regularly identify new disease targets.
  • We are bullish on the stock as the recent pullback in shares offers an attractive long-term buying opportunity.
  • Looking for more investing ideas like this one? Get them exclusively at Conviction Dossier. Learn More »

Futuristic laboratory equipment - coronavirus testing
Photo by janiecbros/E+ via Getty Images

BridgeBio Pharma, Inc. (NASDAQ:BBIO) focuses on the development of medicines to treat genetic diseases and genetically defined cancers. New techniques in the field are allowing researchers to discover associations between specific gene variations

Add some conviction to your trading! We sort through +4,000 ETFs/CEFs along with +16,000 U.S. stocks/ADRs to find the best trade ideas. Click here for a two-week free trial and explore our content at the Conviction Dossier.

This article was written by

Dan Victor, CFA profile picture

Dan Victor, CFA is a market professional with more than 15 years of investment management experience across major financial institutions in research, strategy, and trading roles.

Dan leads the investing group Conviction Dossier, where his focus is on helping investors stay ahead of market trends and inflection points. Dan’s investing vehicles of choice are growth stocks, tactical exchange-traded funds, and option spreads. He shares model portfolios and research to help investors make better decisions, via his Investing Group’s active chat room.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in BBIO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (4)

TruffelPig profile picture
You got really unlucky on the timing but now is the time to go all in.
At some point, this will be a buy, but not quite yet.
Dan Victor, CFA profile picture
Thanks for reading. If you enjoyed the article consider following to hear about our next Seeking Alpha idea.- BOOX
Jasvinder15 profile picture
@BOOX Research I really enjoyed the article and it was in line with my own research and projections. But my conclusion was really different. I think it's way overvalued considering the R&D expenses. Let's see how it goes in the long run.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About BBIO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BBIO

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.